Skip to main content
BMS, Tsinghua expand deal on autoimmune diseases, cancer

Bristol-Myers Squibb has expanded its 2012 collaboration with Tsinghua University to add identification, validation, discovery and development of new autoimmune disease and cancer targets. Under the expanded deal, BMS gets the option to license exclusive rights to compounds discovered in the agreement.

Full Story: